Second-line oritinib demonstrated potential clinical benefit in advanced EGFR-mutated NSCLC Presented ByProf. Caicun Zhou, Shanghai Pulmonary Hospital, China TrialPhase 2 ConferenceELCC 2022 25 May, 2022 12:40